In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Conjugate Pemvidutide | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Conjugate | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 43 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 7 (7 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 8 · 2 active | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 27 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Pemvidutide | Liraglutide |
|---|---|---|
| Body weightMetabolic and weight | 422 | 83481717 |
| Adverse events |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
77 |
50449311 |
| Liver fat and liver functionLiver | 281711 | 1361279 |
|---|
| LipidsMetabolic and weight | 22 | 14313733 |
|---|
| Inflammation markersLiver | 22 | 117100152 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Pemvidutide | Liraglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | −6.2% Body weight reduction · Shown as a change. The study reports a body weight reduction of this size. · pemvidutide, week 24 24 weeksn not reported2025 | −5.8% Mean weight change · liraglutide 3.0 mg Placebo: −1.5% Dose studied: 3.0 mg56 weeksn = 3962020 |
| Liver fat and liver functionLiverCompared as: value in the arm that got the peptide, in % | 52% MASH resolution without fibrosis worsening · pemvidutide 1.8 mg, week 24 Placebo, week 24: 20% Dose studied: 1·8 mg24 weeksn = 1712025 | |
| Adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 1% Discontinuations due to adverse events · pemvidutide 1·8 mg (1 of 85) Placebo (2 of 86): 2% Dose studied: 1·8 mg24 weeksn = 1712025 |
−6.2%
Body weight reduction · Shown as a change. The study reports a body weight reduction of this size. · pemvidutide, week 24
24 weeksn not reported2025
−5.8%
Mean weight change · liraglutide 3.0 mg
Placebo: −1.5%
Dose studied: 3.0 mg56 weeksn = 3962020
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Pemvidutide | Liraglutide |
|---|---|---|
| Inflammation markersImmune and inflammationCompared as: difference from placebo, in ng/ml | No randomized trial result 2 results from other study designs. | 14.9 ng/ml Serum NGAL difference Dose studied: 3 mg/d52 weeksn = 1272025 |
39% Resolution of definite NASH Placebo: 9% Dose studied: 1·8 mg daily48 weeksn = 452016 |
7.9%
Discontinuation due to adverse events
Dose studied: up to 1.8 mg/dup to 104 weeksn = 1,9912022
52%
MASH resolution without fibrosis worsening · pemvidutide 1.8 mg, week 24
Placebo, week 24: 20%
Dose studied: 1·8 mg24 weeksn = 1712025
39%
Resolution of definite NASH
Placebo: 9%
Dose studied: 1·8 mg daily48 weeksn = 452016
1%
Discontinuations due to adverse events · pemvidutide 1·8 mg (1 of 85)
Placebo (2 of 86): 2%
Dose studied: 1·8 mg24 weeksn = 1712025
7.9%
Discontinuation due to adverse events
Dose studied: up to 1.8 mg/dup to 104 weeksn = 1,9912022
| LipidsCardiovascularCompared as: difference from placebo, in lipids | No randomized trial result 2 results from other study designs. | 21 lipids Lipids decreased 26 weeksn = 1022021 |
|---|
No randomized trial result
2 results from other study designs.
14.9 ng/ml
Serum NGAL difference
Dose studied: 3 mg/d52 weeksn = 1272025
No randomized trial result
2 results from other study designs.
21 lipids
Lipids decreased
26 weeksn = 1022021
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 8 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Altimmune, Inc.1,800 participants30 Jul 2026 to est. Dec 2032
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Altimmune, Inc.212 participants27 Jul 2023 to 25 Nov 2025
Non-Alcoholic Steatohepatitis (NASH)
Altimmune, Inc.121 participants16 Jun 2025 to est. 30 Sept 2027
Alcohol-associated Liver Disease
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.